Pharming Announces Instructions for Exchanging Listed Ordinary Shares into Nasdaq Listed ADSs | ANP Pers Support perssupport.nl - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from perssupport.nl Daily Mail and Mail on Sunday newspapers.
Share this article
Share this article
BILTHOVEN, Netherlands, Dec. 22, 2020 /PRNewswire/ Intravacc, one of the world s leading translational research and development vaccine organisations, with an extensive track record in developing infectious diseases vaccines, today announced that it will become a Public Shareholding Company with limited liability (B.V.) as of January 1
st, 2021. The Dutch State will be sole shareholder. Until now Intravacc has been separate entity under the responsibility of the Dutch Ministry of Health, Welfare and Sport.
As a result of this privatization process, all assets, employees, intellectual property, and contracts and agreements will be transferred to the new company on January 1
Pharming Reports on Extraordinary General Meeting of Shareholders
LEIDEN, Netherlands, Dec. 11, 2020 /PRNewswire/ Pharming Group N.V. ( Pharming or the Company ) (Euronext Amsterdam: PHARM) announces that at its Extraordinary General Meeting of shareholders (EGM), held today, all proposals were approved. As a result, the one-tier board structure has become effective, and Barbara Yanni and Mark Pykett have been appointed as non-executive board members.
A recording of the webcast and the presentation slides from today s EGM are available on the Company s website: https://www.pharming.com/investors/shareholder-meetings
About Pharming Group N.V.
Pharming Group N.V. is a global, commercial stage biopharmaceutical company developing innovative protein replacement therapies and precision medicines for the treatment of rare diseases and unmet medical needs.
Pharming Reports on Extraordinary General Meeting of Shareholders | ANP Pers Support perssupport.nl - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from perssupport.nl Daily Mail and Mail on Sunday newspapers.
(2)
Highlights:
First patient treated in second clinical trial globally investigating the use of RUCONEST to prevent severe SARS-CoV-2 infections in hospitalised patients with confirmed COVID-19
Planned expansion to multiple centres across the US
LEIDEN, The Netherlands, Dec. 10, 2020 /PRNewswire/ Pharming Group N.V. ( Pharming or the Company ) (Euronext Amsterdam: PHARM) today announced that the first patient has been enrolled in a randomised, open label, parallel group, controlled, pilot clinical trial in up to 120 patients hospitalised with confirmed COVID-19 treated with RUCONEST (recombinant human C1 inhibitor) for the prevention of severe SARS-CoV-2 infections at the Valley Hospital in Ridgewood, New Jersey in the United States.